Anesthesia monitoring devices market size is expected to reach USD 1.9 billion by 2024

The anesthesia monitoring devices market is expected to reach USD 1.9 billion by 2024, according to a new report by Grand View Research, Inc. The growing geriatric population base and the spiraling number of surgeries are anticipated to boost the market growth. Geriatric patients are the target population for this industry as they are highly prone to various chronic disorders and are at a higher risk of developing complications.

The rising awareness amongst the physicians about the various factors that affect patient outcomes, such as the choice of anesthetic drug, the appropriate route of administration, and the right dose of the anesthetic agent, as well as the monitoring of the depth of anesthesia is likely to accelerate the growth of the market during the forecast period.

Technological advancements in terms of accuracy, portability, and affordability have resulted in the increased usage of these monitoring devices. For instance, the introduction of the new generation, microprocessor-based intelligent anesthesia systems with integrated monitors enables monitoring of various parameters along with the precisely-controlled administration of the anesthetic agent.

view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/anesthesia-monitoring-devices-market

Further key findings from the study suggest:

• Amongst the product type segments, the advanced anesthesia monitors segment held a lucrative share of over 60.0% in 2015 owing to its durability, reliability, and accuracy. Moreover, these devices monitor various significant parameters such as oxygen saturation level, carbon dioxide level, heart rate, and blood pressure.

• The hospitals in the end-use segment exhibited remunerative growth in 2015; this can be attributed to the presence of advanced diagnostic and therapeutic medical technologies that enables both, faster and accurate diagnosis. Moreover, the availability of these advanced systems coupled with the presence of skilled personnel contributes towards profitable growth of this segment.

• North America dominated the overall market with a revenue share of over 35.0% in 2015 owing to the presence of well-developed health care settings and the presence of a favorable reimbursement network, government funding, and increasing health awareness levels amongst the people.

• However, Asia Pacific is anticipated to be the fastest growing region with a CAGR of about 11.0% over the forecast period. The economic developments and the advancing healthcare system with the aid of supportive government initiatives are collectively anticipated to further assist the growth in this region.

• Some key players operating in the anesthesia monitoring devices market include Masimo Corporation, Infinium Medical, Inc., Medtronic plc, GE Healthcare, Nihon Kohden Corporation, Philips Healthcare, Mindray Medical International Ltd., Drägerwerk AG & Co. KGaA, and Schiller AG. New product development, mergers, and collaborations are some key initiatives taken to sustain themselves in the competition.

• For instance, Masimo Corporation incorporated Oxygen Reverse Index (ORI) which measures the oxygen levels and provides real-time information with regard to the patient’s oxygen reserve in synchronization with the partial pressure of oxygen to prevent hyperoxia conditions (oxygen levels above normal) in patients that are receiving auxiliary oxygen supply whilst undergoing surgery.

Reference Links:

http://www.grandviewresearch.com/industry-analysis/anesthesia-monitoring-devices-market

Breast imaging market is expected to reach USD 7.3 billion by 2024

The global breast imaging market is expected to reach USD 7.3 billion by 2024, according to a new report by Grand View Research, Inc. The increasing incidences of breast cancer coupled with the continual product improvements being launched and the numerous R&D innovation initiatives being undertaken in the field of cancer are expected to collectively boost the growth of the market over the forecast period.

In 2012, the WHO estimated that around 53.0% of the global women population (1.8 billion women) is anticipated to suffer from breast cancer over their lifespan. This alarmingly rising rate is expected to be the preliminary driver for this market over the forecast period.

The rising base of the geriatric population is another high impact rendering driver of the breast imaging market. A study by the NCBI (National Center for Biotechnology Information) stated that the incidence of breast cancer is higher in patients above the age group of 45.

Increasing expenditure on R&D coupled with government funding are the other vital factors expected to trigger market growth over the forecast period. In 2013, the National Institute of Health, in the U.S. provided a grant amounting to USD 5.6 billion to conduct research on breast cancer. Digital mammography is one of the technologies gaining popularity as compared to other technologies, which is expected to positively reinforce this market’s growth.

However, the high cost of the existing imaging systems coupled with the stringent regulatory policies governing the approval of new products and marketing are predicted to slowdown growth.

view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market

Further key findings from the study suggest:

• The 3D tomosynthesis segment is identified as the fastest growing segment. This technology offers enhanced efficiency and higher diagnostic accuracy in comparison to other available technologies, which is expected to aid market growth.
• North America is likely to dominate throughout the forecast period with a revenue share of over 30.0% by 2024.Government initiatives including the precision medicine initiative, started by President Obama in 2015, promotes the development of personalized medicine, which is anticipated to foster market growth.
• Asia Pacific is anticipated to grow at the fastest rate of12.0% over the forecast period. The Increasing number of investments in the healthcare sector coupled with the rising awareness of breast cancer and other associated conditions is anticipated to propel the market growth in this region.
• Some major players of the market are Siemens Healthcare, GE Healthcare, Dilon Technologies, Inc., Hologic, Inc., Gamma Medica, Inc., Fujifilm Holdings Corporation, SonoCine, Inc., Philips Healthcare, Toshiba Corporation, and Aurora Imaging Technology, Inc.
• In order to gain a competitive advantage in the market, the key industry players are adhering to mergers, acquisitions and collaborative agreements. For instance, in January 2016, Gamma Medica, Inc. entered into a contract with Alpha Imaging Technology Corp. for the commercialization of its new product, Luma GEM.

Reference Links:

http://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market

Breath analyzer market growth is expected to reach USD 11.3 billion by 2024

The global Breath Analyzer Market is expected to reach USD 11.3 billion by 2024, according to a new report by Grand View Research, Inc. Major drivers of the market include the demand for breath analyzers arising from the law enforcement agencies as well as other institutions, such as schools, sports, and offices, to minimize alcohol abuse and ensure safety in workplace settings. 

The fuel cell technology has been widely used in professional breath analyzers as it offers accuracy, alcohol specificity, and portability. Moreover, the semiconductor sensor technology offers affordable breath alcohol screening devices that are mostly used by private consumers. Breath analyzers that use infrared spectroscopy are currently limited to the law enforcement agencies owing to their high cost and large device size. 

Breath Analyzer Market

The growing demand for quick and easy methods for the primary diagnosis of diseases, such as asthma, chronic obstructive pulmonary disease, and cancer is augmenting the growth of the global market. In addition, the rising adoption of breath analyzers in smoking cessation programs to detect carbon monoxide in the exhaled air is augmenting the market growth. 

Uncertainty with regard to the accuracy of the devices, the ambiguous laws about installing these devices in offices, and the high prices attached to infrared spectroscopy are the factors that challenge the growth of the global market. Many of the drug detection devices that identify the presence of drugs in the exhaled breath are still in the developmental phase as the detection technology used will depend on the type of the drug. Hence, this poses some uncertainty for the success of these devices. 

Further key findings from the study suggest:

• In 2015, the fuel cell technology segment accounted for the largest share of the market at31.8%. The dominance of the segment is attributed to the popularity of this technology owing to its accuracy and user-friendly product designs.
• The medical application segment is expected to witness the fastest growth from 2016 to 2024 owing to the rapid development of disease diagnostics, such as breath analyzers for asthma and Chronic Obstructive Pulmonary Diseases (COPD)
• North America captured the largest market share at over half of the total revenue in 2015 and is expected to maintain its dominance throughout the forecast period. The presence of a large number of major market players, strict laws for road traffic safety, and a high adoption rate of the advanced technologies are the factors driving the market growth in this region.
• The Asia Pacific market is expected to grow at a lucrative CAGR of around 32% during the forecast period. The existence of a large untapped market and the growing awareness regarding the commercially available and technically advanced products are some of the major drivers of the market in the region.
• The presence of a large number of local manufacturers in the Asia Pacific region offering low-cost breath analyzers in comparison to other manufacturers based in developed countries is one of the factors expected to propel the exports from this region
• Some key players in the Breath Analyzer Market include Dragerwerk AG & Co. KGaA, Intoximeter, Inc., Alcovisor, Quest products, Inc., Lifeloc Technologies, Akers Biosciences, Inc., MPD, Inc., AK GlobalTech Corp., Alcohol Countermeasure Systems Corp., and EnviteC-Wismar GmbH.

Reference Links: 

http://www.grandviewresearch.com/industry-analysis/breath-analyzer-market 

Chemoinformatics market size is expected to reach over USD 21.18 billion by 2024

The global chemoinformatics market is expected to reach over USD 21.18 billion by 2024 according to a new report published by Grand View Research, Inc. Some major determinants influencing the market growth include the constantly improving modern drug development processes, increasing use of in-silico techniques in research, and the advantages associated with employing the chemoinformatics approach, such as the reduction in the overall R&D expenditure during the drug development process.

The ever increasing growth of the drug development market will boost the demand for chemoinformatics owing to its numerous applications in drug designing at various stages. Right from target identification to its development as a potential drug candidate, chemoinformatics tools play a crucial part.

The significant contributions of the varying in silico tools in the generation of hits through the High Throughput Screening(HTS) process, target compound selection, virtual structure generation, Pharmacokinetic property and toxicity prediction of chemical compounds, and the quantitative-structure relationship determination have been a major driving force for the growth of the chemoinformatics market.

The heavy costs incurred along with the long time span invested in the drug discovery process has made the integration of the chemoinformatics techniques essential in the research activities. It aids the scientists and chemical researchers in making better decisions pertaining to drug discovery and other related research studies. Furthermore, the increasing demand for efficient and effective medicines, rising investments in R&D, growing geriatric population, and the burgeoning number of individuals with lifestyle related diseases are expected to positively reinforce the market growth. The key applications of the chemoinformatics tools and softwares in drug designing and discovery has been its largest application and is expected to grow further with further advances in the drug discovery process.

Chemoinformatics has made marked contributions to the areas of chemical drug development and research. The growth of this field is driven by the continually generated raw data in screening operations and research studies. Chemoinformatics in silico tools aid in effective data management, which facilitate data retrieval and analysis thus providing large databases of accessible information to scientists involved in both, the drug development process and other research related studies.

The development of three dimensional chemical structure databases has been a significant achievement in the field of chemoinformatics as it has significantly aided the research process. Applications of chemoinformatics platforms in computer-assisted synthesis designing, computer-assisted structure elucidation, and chemometrics have further contributed to the market growth.

The advancements in computational technology have been a high impact rendering driver for the market growth. In this direction, the development of super computers and silicon graphics computer for calculations, 3D structure generation, molecular graphics, and complex data display have been pivotal in propelling the growth of the chemoinformatics market. With the advent of advanced WEB technologies and their incorporation in the in-silico computational techniques have totally revolutionized this field.

The increasing needs for advanced and efficient technologies to yield better results has made the chemoinformatics area an indispensable part of the pharmaceutical industry. The surging need for therapeutically-effective medicines coupled with the increasing investments in the R&D area and the advancements in computer technologies provide lucrative opportunities to the market for it to grow and flourish in the near future.

Further key findings from the study suggest:

• In 2015, North America dominated the chemoinformatics market with a revenue share of over 36% on account of the following factors:  the high investments pertaining to the R&D initiatives, technological advancements, the presence of major players in the drug manufacturing industry, and the increasing prevalence of lifestyle-related diseases. With respect to the global R&D spending, North America holds the largest share. Also, it holds a major share in the ADME-toxicology market that further spurs the growth of the chemoinformatics market.

• Asia Pacific is identified as one of the fastest growing regional markets, growing at a lucrative CAGR of 18.3% during the forecast period. The growth of this market can be attributed to the growing research activities being conducted in economies, such as India, China, and Singapore. The key advantages associated with undertaking research activities in these countries include the low manufacturing and labor costs and the less stringent regulations, which attract many multinational players to the Asia Pacific region. Additionally, the government initiatives and funds that are deployed to improve the R&D infrastructure will further drive the market growth.

• Key players operating in the market include Agilent Technologies, Inc., BIOVIA (Accelrys), Bio-Rad Laboratories, Inc., CambridgeSoft Corp., ChemAxon, Inc., ACD/Labs, Inc., Schrödinger, LLC, and Chemical Computing Group, Inc. Additionally, the rising demand for in-silico techniques in the research sector is expected to provide new market entrants with profitable opportunities thereby driving the market growth.

Reference Links:

http://www.grandviewresearch.com/industry-analysis/chemoinformatics-market

Smoking cessation and nicotine de-addiction market worth is expected to reach over USD 21.8 billion by 2024

The global smoking cessation and nicotine de-addiction market is expected to reach over USD 21.8 billion by 2024 according to a new report by Grand View Research, Inc. 

The base of population addicted to smoking is rapidly increasing across the globe. This population subset majorly includes teenagers and the working population. Smoking-related mortality is very high. The increasing desire to quit smoking and the numerous health complications associated with smoking serve as strong incentives for companies to introduce novel smoking cessation products, such as Revolymer, which has introduced the next generation nicotine gums to help smokers quit smoking. The launch of these improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market. 

The growing incidence of target diseases such as chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, and the increasing awareness pertaining to the hazardous side-effects of smoking are the factors expected to promote market expansion. Educational institutions remain active in organizing various campaigns and programs to spread information about the harmful effects and consequences of smoking so as to increase young population awareness. 

view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/smoking-cessation-and-nicotine-de-addiction-products-market

Further key findings from the study suggest:

• Nicotine Replacement Therapy (NRT) dominated the smoking cessation and de-nicotine addiction product market in 2015. Majorly used NRT products include nicotine chewing gums and the transdermal patches. Increased availability and the introduction of the ingestible nicotine products with different flavors are the factors responsible for its large market share.
• The e-cigarette segment is anticipated to grow at a CAGR of19.0% over the forecast period. The major factors responsible for the growth of the E-cigarette market include the introduction of second and third generation e-cigarettes, the availability of various flavored products, the presence of numerous vendors operating and selling e-cigarettes under different brand names.
• North America held a large market share of over 35.0% in 2015 owing to the high awareness levels of nicotine de-addiction products with around 90% of the U.S. population were identified as aware of e-cigarettes in 2015
• Asia Pacific is the fastest growing market. The registration of nicotine de-addiction products and e-cigarettes as well as the strengthening of the company distribution channels in countries, such as China, India, and Australia are expected to support the growth over the forecast period
• Some key players of this market are Pfizer, Inc., Cipla Ltd., Novartis International AG, GlaxoSmithKline plc, Takeda pharmaceutical Company Ltd., McNeil AB, Revolymer plc, Imperial Tobacco Ltd., and VMR products, LLC
• The market players are making slow but steady progress in the e-cigarette market by focusing on the development, commercialization, and distribution of the FDA approved nicotine products. For instance, in 2014, Victory Electronic Cigarettes Corporation acquired Ten Motives Ltd. with an aim to expand their distribution channels and attain wider market coverage.

Reference Links:

http://www.grandviewresearch.com/industry-analysis/smoking-cessation-and-nicotine-de-addiction-products-market

Point of care (PoC) diagnostics market size is anticipated to reach USD 20.9 billion by 2024

The global point of care (PoC) diagnostics market is anticipated to reach USD 20.9 billion by 2024, according to a new report by Grand View Research, Inc. Rise in the R&D funding and research activities amongst the market players in order to introduce novel POC tests and devices for ease of disease detection and monitoring is expected to fuel industrial progress through to 2024.

Point of Care (PoC) Diagnostics Market

Moreover, the introduction of favorable regulatory initiatives in order to promote the development and adoption of POC diagnostic tests is anticipated to propel growth in the coming years. Furthermore, advancement of diagnostic laboratories and adaptation of more integrated and automated lab systems are also factors expected to fuel demand for advanced workflow systems and drive the digital pathology and workflow segment through to 2024.

view summary of this report, click the link below:

http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry

Further key findings from the report suggest:

• Glucose testing accounted for the largest share in revenue in 2015 owing to the higher prevalence of diabetes. Presence of significant product portfolio pertaining to glucose testing in the market and the presence of a number of major players as wells as local manufacturers from different regions are factors attributive to contribute substantially to the revenue generated.

• Hb1Ac POC tests are more reliable for glucose testing and due to the vast patient base for diabetes management, this segment is second in terms of revenue generation in the POC market only to its counterpart. Owing to the presence of glucose testing segment as a potential market and growing cost effectiveness of Hb1Ac tests, it is expected that over the coming decade it will witness considerable growth in demand and usage 

• POC tests for infectious disease testing, is another segment of prime activity in the point of care industry. This segment includes rapid diagnostic tests for a considerable number of diseases including HIV, HBV, RSV, HPV, Influenza, HCV, MRSA, TB/dr-TB & HSV among others.

• Owing to the growing incidence of a number of infectious diseases, initiatives taken by a number of governments to implement early diagnosis and screening, and development of rapid tests able to distinguish between a wide number of pathogens this segment has been observed to be at the demand receiving end in the industry for the better half of the last decade and is only expected to witness growth in demand.

• Hospitals are estimated to be the dominant end-users for POC diagnosis industry owing to higher penetration of products and comparatively higher usage rate for disease monitoring and diagnosis.

• North America dominated the market in 2015, with over 43% of total revenue. Presence of major entities with widespread distribution network coupled with significant number of research endeavors carried out in the U.S is supportive for the largest share of region. Moreover, point of care diagnostics is a relatively more advanced segment of in vitro diagnostics and owing to the presence of high R&D expenditure, availability of a technologically advanced healthcare infrastructure along with the presence of a number of ongoing government funded research projects are factors accounting for the region’s large share.

• Asia Pacific is projected to witness lucrative growth in the coming years owing to the developments carried out in developing economies herein in order to develop the healthcare infrastructure and reduce the incidence of target diseases.

• Major participants of this market include Roche, Abbott Laboratories, Siemens Healthcare, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Alere Inc., Qiagen N.V., Spectral Diagnostics, Instrumentation Laboratory, Nova Biomedical, Nipro Diagnostics, Trinity Biotech, and Sekisui.

• Participants are involved in adopting competitive strategies in order to enhance the market presence. These companies are also involved in collaborations with hospitals in order to maintain the market share.

• For instance, in April 2015, Nipro diagnostics participated in an industry event named AMCP (Academy of Managed Care Pharmacy) in support of providing care to the patients with diabetes.

Reference Links:

http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry

Medical automation market growth is expected to reach USD 79.4 billion by 2024

The global medical automation market is expected to reach USD 79.4 billion by 2024, according to a new report by Grand View Research, Inc. The increasing demand for accuracy and reproducibility required during medical procedures is the high impact rendering driver for the medical automation market. 

The rising adoption of these devices is attributed to the advantages associated with automated systems. For example, the automation of tedious tasks such as sampling, monitoring of quality, quantity, packaging and labeling, and scanning of medicines and devices, have reduced human efforts and increased speed and accuracy, which has led to increased dependency on these automated systems. 

Medical Automation Market Growth

Moreover, the growing global prevalence of chronic conditions such as diabetes, cancer, arthritis, and chronic obstructive pulmonary disease (COPD) is further pushing the demand for therapeutic, laboratory and pharmacy automated medication systems, which are faster and more productive. As per the World Health Organization (WHO) estimates, cardiovascular diseases (CVDs) is the leading cause of mortality around the globe; in addition, an exponential rise has been witnessed in the diabetes cases from 108 million in 1980 to 422 million in 2014. The aforementioned factors are responsible for creating the need for automated medical equipments over the forecast period. 

Furthermore, with the advent of technologically advanced defibrillators and ablation therapies, this market is expected to gain swift growth in its market share in the near future. For instance, automation in the following pharmacy-based functions, medication dispensing, storage, and retrieval enables traceability and tracking, which in turn improves patient safety and reduces errors. Furthermore, there is an increased focus on incorporating automation in hospitals due to the associated benefits, such as reduction of errors and operational costs; these factors altogether are expected to present this market with high growth opportunities in the near future.

View summary of this report, click the link below: 

http://www.grandviewresearch.com/industry-analysis/medical-automation-market

Further key findings from the study suggest:

• The therapeutic segment was observed to dominate in terms of revenue share in 2015owing to the high usage rate of automated devices in the non-surgical procedures, such as external defibrillators, an implantable cardioverter, and wearable/ implantable drug pumps 

• On the other hand, the medical logistics and training segment is expected to grow at a lucrative CAGR of over 10.0%. The rising adoption of advanced systems, such as Pneumatic Tube Systems (PTS) used in material transportation and Real Time Location System (RTLS) in location-tracking, contributes towards the overall medical automation market growth during the forecast period. 

• The research laboratories and institutes segment is also identified as a lucrative segment due to, the rising demand for automated research laboratories that are helpful in the detection and the treatment of chronic diseases. These laboratory automated systems help in reducing demand and supply gaps by mechanization, which yields rapid results and increases overall productivity. This is expected to further enhance its usage over the forecast period. 

• With an aim to address the increasing demand for advanced molecular diagnostic techniques in cancer, the Leiden University Medical Center have recently succeeded in isolating DNA and RNA from small tissue samples using a high-throughput, fully automated solution by Siemens. Innovations like these are expected to present the market with significant growth opportunities. 

• Some key players in this industry include Accuray, Inc., Tecan Group Ltd., Medtronic Plc., Swisslog Holding AG, GE Healthcare, Intuitive Surgical, Inc., Stryker Corporation, Siemens AG, Koninklijke Philips N.V., and Danaher Corporation. 

• These industry players are adopting strategies such as technological innovation, new product launches, and strategic collaborations including mergers and acquisitions to capitalize untapped opportunities. For instance, in July 2015, Medtronic Plc. acquired RF Surgical Systems, Inc., for further expansion of its business and with the aim of capturing a huge market share of the medical automation market in the coming years. 

To get full details at: 

http://www.grandviewresearch.com/industry-analysis/medical-automation-market